Monograph
R03CC12 - Bambuterol |
Propably not porphyrinogenic |
PNP |
Rationale
Only limited hepatic load. Probably non-CYP metabolism. About 10 % of the absorbed dose gives rise to terbutaline ( i.e. 0.2-0.5 mg) "Rather low dose in large part not metabolised. No data pointing to CYP-interaction. One reference: authorised."
Chemical description
Long-acting adrenergic bronchodilator for systemic use (tabl. 10 - 20 mg, mixture 1mg/mL). used in bronchial asthma where glucocorticoide effect is insufficient. Prodrug to the beta-receptor agonist terbutaline. Only about 20 % of the dose is absorbed. About 1/3 is metabolized in the intestinal wall to intermediary metabolites. About 10% gives rise to terbutaline.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom© NAPOS 2024